Study summary

The purpose of the study was to evaluate the efficacy of enzalutamide in participants with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS).

This study also evaluated the safety of enzalutamide; pharmacokinetics of enzalutamide and the active metabolite N-desmethyl and Progression Free Survival (PFS) of enzalutamide as compared to placebo in participants with advanced HCC.

Additional Study Details

Phase
Phase 2
Product
  • Enzalutamide
  • Placebo
  • Type
    Interventional
    Masking
    Double (Participant, Investigator)
    Enrollment number
    165
    Show Additional Study Details

    Study documents

    Scientific Results Summary 2
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site KR82004
      Seoul, Republic of Korea, 05505
      Completed
      Site US10017
      Minneapolis, MN, United States, 55455-0362
      Completed
      Site KR82002
      Seongnam-Si, Gyeonggi-do, Republic of Korea, 013620
      Withdrawn
      Site ES34002
      Santiago de Compostela, Spain, 15706
      Completed
      Site TW88605
      Tainan, Taiwan, Province of China, 710
      Completed
      Site IT39004
      Pavia, Italy, 27100
      Completed
      Site US10008
      Portland, OR, United States, 97239
      Completed
      Site GB44007
      Birmingham, United Kingdom, B15 2WB
      Completed
      Site ES34006
      Cordoba, Cordoba, Spain, 14004
      Completed
      Site US10003
      San Francisco, CA, United States, 94115
      Withdrawn
      Site US10002
      Spartanburg, SC, United States, 29303
      Completed
      Site ES34003
      Barcelona, Barcelona, Spain, 08035
      Withdrawn
      Site IT39001
      Napoli, Italy, 80131
      Completed
      Site CA15001
      Toronto, ON, Canada, M5G2C4
      Completed
      Site CA15002
      Montreal, QC, Canada, H3T 1E2
      Completed
      Site KR82006
      Seoul, Republic of Korea, 03080
      Completed
      Site US10009
      Skokie, IL, United States, 60077
      Completed
      Site IT39005
      Benevento, Italy
      Withdrawn
      Site US10015
      Nashville, TN, United States, 37208
      Completed
      Site IT39002
      Milan, Italy, 20132
      Withdrawn
      Site US10011
      St. Louis, MO, United States, 63104
      Completed
      Site ES34004
      Madrid, Spain, 28222
      Completed
      Site US10001
      San Juan, PR, United States, 00927
      Completed
      Site US10021
      Lebanon, NH, United States, 03756-1000
      Completed
      Site GB44008
      London, United Kingdom, W12 OHS
      Withdrawn
      Site US10022
      San Antonio, TX, United States, 78215-1639
      Withdrawn
      Site US10010
      Columbus, OH, United States, 43210
      Completed
      Site GB44005
      Manchester, United Kingdom, M20 4BX
      Completed
      Site US10019
      Philadelphia, PA, United States, 19104
      Withdrawn
      Site US10020
      Evanston, IL, United States, 60201
      Completed
      Site IT39008
      Rozzano, Milan, Italy, 20089
      Completed
      Site HK85204
      Shatin, Hong Kong, 999077
      Completed
      Site CA15003
      Montreal, Canada, H4A 3J1
      Completed
      Site IT39006
      Milano, Italy, 20122
      Completed
      Site US10014
      Philadelphia, PA, United States, 19104
      Withdrawn
      Site HK85205
      Tuen Mun, Hong Kong, 999077
      Terminated
      Site US10016
      Milwaukee, WI, United States, 53226-3522
      Completed
      Site TW88603
      Douliu, Taiwan, Province of China, 640
      Completed
      Site HK85202
      Kowloon, Hong Kong, 999077
      Completed
      Site TW88604
      Taipei City, Taiwan, Province of China, 10048
      Completed
      Site GB44004
      London, United Kingdom, SE5 9RS
      Completed
      Site GB44002
      Wirral, United Kingdom, CH63 4JY
      Completed
      Site KR82001
      Seoul, Republic of Korea, 06591
      Completed
      Site KR82007
      Seoul, Republic of Korea, 03722
      Completed
      Site IT39011
      Padova, Italy, 35128
      Completed
      Site TW88606
      Tainan, Taiwan, Province of China, 704
      Completed
      Site KR82005
      Seoul, Seoul Teugbyeolsi, Republic of Korea, 135-710

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?